- Home
- FBNC vs LQDA Comparison
FBNC vs LQDA Comparison
Compare FBNC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBNC | LQDA |
|---|---|---|
| Founded | 1934 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FBNC | LQDA |
|---|---|---|
| Price | $53.00 | $32.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $56.67 | $37.40 |
| AVG Volume (30 Days) | 181.0K | ★ 1.8M |
| Earning Date | 01-28-2026 | 11-03-2025 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $364,799,000.00 | $69,216,000.00 |
| Revenue This Year | $40.17 | $904.79 |
| Revenue Next Year | $12.16 | $188.25 |
| P/E Ratio | $21.46 | ★ N/A |
| Revenue Growth | 0.59 | ★ 343.41 |
| 52 Week Low | $34.50 | $10.37 |
| 52 Week High | $56.45 | $35.54 |
Technical Indicators
Market Signals| Indicator | FBNC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 62.63 | 59.75 |
| Support Level | $50.79 | $30.50 |
| Resistance Level | $52.08 | $35.54 |
| Average True Range (ATR) | 1.29 | 1.71 |
| MACD | 0.19 | 0.07 |
| Stochastic Oscillator | 95.38 | 63.62 |
Price Performance
Historical ComparisonAbout FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.